The many unanswered questions related to the German skin cancer screening programme

Andreas Stang, Claus Garbe, Philippe Autier, Karl Heinz Jöckel

Research output: Contribution to journalArticle

11 Citations (Scopus)

Abstract

In 2008, the first nationwide skin cancer screening (SCS) programme in the world was established in Germany. The main reason to implement the SCS programme in Germany was the expected reduction of costs of care due to earlier detection of skin cancer. The aim of this commentary is to raise and discuss several unanswered questions related to the German SCS programme. The evidence of a temporary mortality decline of skin melanoma after SCS in Schleswig-Holstein is lower than previously assumed and the temporary decline may have been caused by other factors than screening (e.g. awareness effects, selection bias, data artifact, and random fluctuation). The evaluation of the nationwide effect of SCS on skin cancer mortality is hampered by birth cohort effects and low quality of the routine cause-of-death statistics. The nationwide skin melanoma mortality did not decrease from 2007 through 2014. The time interval between screenings after a screening without pathological findings is unclear. Appropriate research designs are needed that monitor and evaluate the effect of SCS not only on skin cancer mortality but also on other factors that may help to judge the potential benefits and harms of SCS including aggressiveness of therapy, costs of care, quality of life, and stage-specific incidence rates of skin cancer. Furthermore, SCS may profit from a high-risk strategy instead of population-wide screening and from newer technologies for early detection of skin cancer (e.g. dermoscopy).

LanguageEnglish
Pages83-88
Number of pages6
JournalEuropean Journal of Cancer
Volume64
Early online date29 Jun 2016
DOIs
Publication statusPublished - 30 Sep 2016

Fingerprint

Skin Neoplasms
Early Detection of Cancer
Mortality
Germany
Melanoma
Dermoscopy
Costs and Cost Analysis
Cohort Effect
Skin
Selection Bias
Artifacts
Cause of Death
Research Design
Quality of Life
Parturition

Keywords

  • early detection
  • Germany
  • mortality
  • screening
  • skin cancer
  • skin melanoma

Cite this

Stang, Andreas ; Garbe, Claus ; Autier, Philippe ; Jöckel, Karl Heinz. / The many unanswered questions related to the German skin cancer screening programme. In: European Journal of Cancer. 2016 ; Vol. 64. pp. 83-88.
@article{8f67444d4564450fbdb2fdfe16b0eb70,
title = "The many unanswered questions related to the German skin cancer screening programme",
abstract = "In 2008, the first nationwide skin cancer screening (SCS) programme in the world was established in Germany. The main reason to implement the SCS programme in Germany was the expected reduction of costs of care due to earlier detection of skin cancer. The aim of this commentary is to raise and discuss several unanswered questions related to the German SCS programme. The evidence of a temporary mortality decline of skin melanoma after SCS in Schleswig-Holstein is lower than previously assumed and the temporary decline may have been caused by other factors than screening (e.g. awareness effects, selection bias, data artifact, and random fluctuation). The evaluation of the nationwide effect of SCS on skin cancer mortality is hampered by birth cohort effects and low quality of the routine cause-of-death statistics. The nationwide skin melanoma mortality did not decrease from 2007 through 2014. The time interval between screenings after a screening without pathological findings is unclear. Appropriate research designs are needed that monitor and evaluate the effect of SCS not only on skin cancer mortality but also on other factors that may help to judge the potential benefits and harms of SCS including aggressiveness of therapy, costs of care, quality of life, and stage-specific incidence rates of skin cancer. Furthermore, SCS may profit from a high-risk strategy instead of population-wide screening and from newer technologies for early detection of skin cancer (e.g. dermoscopy).",
keywords = "early detection, Germany, mortality, screening, skin cancer, skin melanoma",
author = "Andreas Stang and Claus Garbe and Philippe Autier and J{\"o}ckel, {Karl Heinz}",
year = "2016",
month = "9",
day = "30",
doi = "10.1016/j.ejca.2016.05.029",
language = "English",
volume = "64",
pages = "83--88",
journal = "European Journal of Cancer",
issn = "0959-8049",

}

The many unanswered questions related to the German skin cancer screening programme. / Stang, Andreas; Garbe, Claus; Autier, Philippe; Jöckel, Karl Heinz.

In: European Journal of Cancer, Vol. 64, 30.09.2016, p. 83-88.

Research output: Contribution to journalArticle

TY - JOUR

T1 - The many unanswered questions related to the German skin cancer screening programme

AU - Stang, Andreas

AU - Garbe, Claus

AU - Autier, Philippe

AU - Jöckel, Karl Heinz

PY - 2016/9/30

Y1 - 2016/9/30

N2 - In 2008, the first nationwide skin cancer screening (SCS) programme in the world was established in Germany. The main reason to implement the SCS programme in Germany was the expected reduction of costs of care due to earlier detection of skin cancer. The aim of this commentary is to raise and discuss several unanswered questions related to the German SCS programme. The evidence of a temporary mortality decline of skin melanoma after SCS in Schleswig-Holstein is lower than previously assumed and the temporary decline may have been caused by other factors than screening (e.g. awareness effects, selection bias, data artifact, and random fluctuation). The evaluation of the nationwide effect of SCS on skin cancer mortality is hampered by birth cohort effects and low quality of the routine cause-of-death statistics. The nationwide skin melanoma mortality did not decrease from 2007 through 2014. The time interval between screenings after a screening without pathological findings is unclear. Appropriate research designs are needed that monitor and evaluate the effect of SCS not only on skin cancer mortality but also on other factors that may help to judge the potential benefits and harms of SCS including aggressiveness of therapy, costs of care, quality of life, and stage-specific incidence rates of skin cancer. Furthermore, SCS may profit from a high-risk strategy instead of population-wide screening and from newer technologies for early detection of skin cancer (e.g. dermoscopy).

AB - In 2008, the first nationwide skin cancer screening (SCS) programme in the world was established in Germany. The main reason to implement the SCS programme in Germany was the expected reduction of costs of care due to earlier detection of skin cancer. The aim of this commentary is to raise and discuss several unanswered questions related to the German SCS programme. The evidence of a temporary mortality decline of skin melanoma after SCS in Schleswig-Holstein is lower than previously assumed and the temporary decline may have been caused by other factors than screening (e.g. awareness effects, selection bias, data artifact, and random fluctuation). The evaluation of the nationwide effect of SCS on skin cancer mortality is hampered by birth cohort effects and low quality of the routine cause-of-death statistics. The nationwide skin melanoma mortality did not decrease from 2007 through 2014. The time interval between screenings after a screening without pathological findings is unclear. Appropriate research designs are needed that monitor and evaluate the effect of SCS not only on skin cancer mortality but also on other factors that may help to judge the potential benefits and harms of SCS including aggressiveness of therapy, costs of care, quality of life, and stage-specific incidence rates of skin cancer. Furthermore, SCS may profit from a high-risk strategy instead of population-wide screening and from newer technologies for early detection of skin cancer (e.g. dermoscopy).

KW - early detection

KW - Germany

KW - mortality

KW - screening

KW - skin cancer

KW - skin melanoma

UR - http://www.scopus.com/inward/record.url?scp=84976345182&partnerID=8YFLogxK

UR - http://www.sciencedirect.com/science/journal/09598049

U2 - 10.1016/j.ejca.2016.05.029

DO - 10.1016/j.ejca.2016.05.029

M3 - Article

VL - 64

SP - 83

EP - 88

JO - European Journal of Cancer

T2 - European Journal of Cancer

JF - European Journal of Cancer

SN - 0959-8049

ER -